Renal Division, Mount Sinai School of Medicine, New York, New York 10029, USA.
Kidney Int. 2010 Jul;78(2):125-7. doi: 10.1038/ki.2010.80.
Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.
目前针对抗体介导的肾移植排斥反应的治疗方法并不完善。Tillou 及其同事给予重组 C1 抑制剂以阻断补体激活，从而防止致敏的狒狒接受肾同种异体移植物后抗体引发的损伤。这些早期但令人鼓舞的结果支持进一步测试补体抑制的安全性和有效性，作为治疗这种疾病的综合策略的一部分，包括在动物模型中和最终在人体中。
